Fig. 3.

Predicted time profile of cord-to-maternal plasma and foetal-to-maternal plasma concentration ratios of efavirenz and thalidomide across the dosing interval during pregnancy. A - Cord-to-maternal plasma and foetal-to-maternal plasma ratios of efavirenz at second trimester; and B - Cord-to-maternal plasma and foetal-to-maternal plasma ratios of efavirenz at third trimester; C - Cord-to-maternal plasma and foetal-to-maternal plasma ratios of thalidomide at second trimester; and D - Cord-to-maternal plasma and foetal-to-maternal plasma ratios of thalidomide at third trimester. Data presented as mean (SD).